Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)
Status:
Completed
Trial end date:
2010-12-14
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy and safety of Etoricoxib compared to
placebo and ibuprofen in the treatment of postoperative pain associated with unilateral total
knee replacement surgery. The hypotheses for this study were that the average pain intensity
difference (at rest) in participants treated with Etoricoxib (120 mg, 90 mg) is superior to
placebo, the average total daily dose of morphine in participants treated with Etoricoxib
(120 mg, 90 mg) is less than in participants treated with placebo, and that Etoricoxib (120
mg, 90 mg) will be generally safe and well tolerated by participants treated for pain
following total knee replacement orthopedic surgery.